

# PARMAX PHARMA LIMITED

Financial statement for the quarter ended 30.09.2015

1	<b>Net Sale / Income from Operation</b>			
	Commission received	-		
	Other income	-	-	
	(A)		-	
2	<b>Other Income</b>	-	-	
3	<b>Total Expenditure</b>			
	(a) Increase / Decrease in stock		-	
	(b) Purchase of Shares & Securities		-	
	(c ) Staff Cost		-	
	Salary & Directors Remuneration	-		
	Staff Welfare	-	-	
	(d) Other Expenditure		108,499.00	
4	(B)		108,499.00	
	<b>Profit (+ or - ) before Dep.(A-B)</b>			(108,499.00)
	<b>Depreciation</b>			-
	<b>Profit (+ or - ) after Dep.</b>			(108,499.00)

# **Unaudited Financial Results (Provisional ) for the Quarter Ended 30.09.2015**

Sr. No	Particulars	3 months ended 30.09.2015	Corresponding 3 months ended 30.09.2014	Six month ended 30.09.2015	Corresponding Six month ended 30.09.2014	Year Ended 31.03.2015
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	a Net Sales/Income from Operations	-	-	-	-	-
	b Other operating Income	-	-	-	-	600,000.00
	<b>Total Income</b>	-	-	-	-	<b>600,000.00</b>
2	Expenditure					
	a : (Increase)/Decrease in Stock-in-Trade	-	-	-	-	-
	b : Consumption of Raw Material	-	-	-	-	-
	c : Purchase of traded goods	-	-	-	-	-
	d : Employees Cost	-	-	-	-	-
	e : Depreciation	-	-	-	-	-
	f : Other Expenditure	108,499.00	29,089.00	211,243.00	123,958.00	240,282.00
	<b>g Total</b>	<b>108,499.00</b>	<b>29,089.00</b>	<b>211,243.00</b>	<b>123,958.00</b>	<b>240,282.00</b>
3	Profit from Operations before other Income, Interest and Exceptional Items (1-2)	(108,499.00)	-	(211,243.00)	(123,958.00)	359,718.00
4	Other Income	-	-	-	-	-
5	Profit before Interest and Exceptional Items (3+4)	(108,499.00)	-	(211,243.00)	(123,958.00)	359,718.00
6	Interest	-	-	-	-	-
7	Profit after interest but before exceptional items (5-6)	(108,499.00)	-	(211,243.00)	(123,958.00)	359,718.00
8	Exceptional Items	-	-	-	-	-
9	Profit from Ordinary Activities before Tax (7+8)	(108,499.00)	-	(211,243.00)	(123,958.00)	359,718.00
10	Tax Expenses	-	-	-	-	-
11	Net Profit from Ordinary Activities after Tax (9-10)	(108,499.00)	-	(211,243.00)	(123,958.00)	359,718.00
12	Extraordinary item	-	-	-	-	-
13	Net Profit for the period (11-12)	(108,499.00)	-	(211,243.00)	(123,958.00)	359,718.00
14	Paid-up Equity Share Capital-[Face Value. Rs 10]	44,545,500.00	39,020,500.00	44,545,500.00	39,020,500.00	39,020,500.00
15	Reserve excluding revaluation reserve	-	-	-	-	941,177.00
16	Basic & Diluted EPS	-	-	-	-	-
17	<b>Public Shareholding</b>					
	Number of Shares					
	% of Shareholding					
18	<b>Promoters and promoter group Shareholding</b>					
	a Pledge / Encumbered					
	Number of Shares	NIL	NIL	NIL	NIL	NIL
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL	NIL
	Percentage of Shares (as a % of the total Share Capital of the Company)	NIL	NIL	NIL	NIL	NIL
	b Non encumbered					
	Number of Shares					
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)					
	Percentage of Shares (as a % of the total Share Capital of the Company)					

## **Notes :**

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at the meeting held on
- There were no investors complaints during the quarter ended 30th Sep 2015
- Previous years figures has been regroup / rearranged wherever necessary.

**PARMAX PHARMA LIMITED**

Alkesh M. Gopani  
Director



Place Hadamtala (Rajkot)

Date:

Clause 41 of the Listing Agreement For companies (Other than Banks)

	Stadalone / Consolidated Statement of Assets and Liabilities Particulars	As at 30-09-2015	As at 31-03-2015
A	<b>EQUITY AND LIABILITIES</b>		
	1 Shareholder's funds		
	(a) Share capital	44545500	40295500
	(b) Reserves and surplus	1,009,223	1,165,894
	© Money received against share warrants	0	0
	<b>Sub- total - Shareholder's funds</b>	45554723	41,461,394
	2 Share application money pending allotment	0	0
	3 Minority interest*	0	0
	4 Non-current liabilities		
	(a) Long-term borrowings	3649177	7899176
	(b) Deferred tax liabilities (net)	0	0
	© Other long-term liabilities	0	0
	(d) Long-term provisions	0	0
	<b>Sub-total-Non-current liabilities</b>	3649177	7899176
	5 Current liabilities		
	(a) Short-term borrowings	0	0
	(b) Trade payables	88162	66232
	(c ) Other current liabilities	0	0
	(d) Short-term provisions	265000	315000
	<b>Sub-total- Current liabilities</b>	353162	381232
	<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>49557062</b>	<b>49741802</b>
B	<b>ASSETS</b>		
	1 Non-current assets		
	(a) Fixed assets	25331120	25331120
	(b) Goodwill on consolidation*	0	0
	(c ) Non-current investments	6000	6000
	(d) Deferred tax assets (net)	0	0
	(e) Long-term loans and advances	734400	734400
	(f) Other non-current assets	8524466	8524466
	<b>Sub-total-Non-current assets</b>	34595986	34595986
	2 Current assets		
	(a) Current investments	0	0
	(b) Inventories	0	0
	© Trade receivables	557360	824150
	(d) Cash and cash equivalents	2157918	2149699
	(e) Short-term loans and advances	12245798	12171967
	(f) Other current assets		0
	<b>Sub-total-Current assets</b>	14961076	15145816
	<b>TOTAL - ASSETS</b>	<b>49557062</b>	<b>49741802</b>



**BHARAT A. SHAH**

B.Com. F.C.A. (DISA)

**B. A. SHAH ASSOCIATES**

**Chartered Accountants**

209 Sapphire, 2<sup>nd</sup> Floor, 21/25 – B, New Jagnath Plot, Rajkot. – 360 001. Ph.: 0281 - 2468261

**Auditor's Limited Review Report**

**On Unaudited Financial Results**

**To**

**The Board of Directors,  
Parmax Pharma Limited**

We have reviewed the accompanying statement of unaudited financial results of **PARMAX PHARMA LIMITED** for the quarter ended on **30th September 2015**. This statement is the responsibility of the Company's Management.

A review of the interim financial information consist principally of applying analytical procedures for the financial data and making enquiries of persons responsible for financial and accounting matters. It is substantially less in scope than audit conducted in accordance with the generally accepted auditing standards, The objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly we do not express such an opinion. Further our review was mainly in regards to the figures of quarter ended 30th September 2015.

During our review we have noticed that:

There are small differences between amounts as per published results and corresponding figured as per the accounts (which are however within tile allowed limit of 10% or Rs. 10 lacs, whichever is higher)

Except this nothing has come to our notice that causes us to believe that the accompanying statements of unaudited financial results have not disclosed the information required to be disclosed in terms of clause 41 of the Listing Agreement including the manner in which it is to be disclosed or that it contain any material misstatement.

**For B A SHAH ASSOCIATES**

Chartered Accountants

FRN.: 109493W

*Bharat A Shah*

**BHARAT SHAH**

PROPRIETOR

M. NO.034222



Date: 31.10.2015

Place: Rajkot